Cancer Drug Endpoints: More Standardization Needed In ctDNA Assessments, US FDA Says

 
• By Sue Sutter
  
Boats at dock
More standardization of circulating tumor DNA assessments has the potential to raise all boats in cancer drug development. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D